Business & Finance
Bio-Rad Received US FDA Clearance for Test to Aid in the Diagnosis of Lyme Disease
4 April 2019 - - US-based life science research and clinical diagnostic products company Bio-Rad Laboratories, Inc. (NYSE: BIO) has received US Food and Drug Administration clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease, the company said.

Lyme disease is the most common tick-borne illness in the United States. Many signs and symptoms of the disease are similar to other conditions so diagnosis can be challenging; however, individuals immediately treated for the disease usually recover rapidly and completely.

The BioPlex 2200 Lyme Total Assay can simultaneously detect multiple targets, providing laboratories valuable information in the early stages of Lyme disease so patients are able to receive treatment as quickly as possible.

Bio-Rad said the release of the BioPlex 2200 Lyme Total assay is the latest offering in Bio-Rad's infectious disease menu for the BioPlex 2200 System, an automated multiplex technology platform.

The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.

Bio-Rad Laboratories is in developing, manufacturing, and marketing a range of innovative products for the life science research and clinical diagnostic markets.

With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare.

Its customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality.

Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding USD 2.2bn in 2018.